As an illustration, the median has a breakdown point of 50%%, whereas the mean has a breakdown point of 0%%.
Patients whose initial BNP level was above the median had a significantly higher hazard of dying (HR 2.96, 95% CI 1.06 8.26).
Using the squamous tumors from the Duke dataset, tumors with SOX2 expression above the median had a statistically-significantly better prognosis than those with SOX2 expression below the median (Fig. 2).
Patients above the median had a significantly shorter survival than patients below the median (P<0.001).
This median had a mean value across participants of 4.05 (±1.68 SD).
Patients below the median had a mean treatment duration of 33.9 (SD 8.6) days and patients above the median had a mean treatment duration of 60.7 (SD 9.7) days.
Patients with LAL activity below median have a significant elevation of serum liver enzymes and a worse lipid profile.
The post-filtering mean quality score was 33.5 and 84%% of reads (median) had a quality score of ≥30.
Patients whose TS mRNA levels in metastatic tumor tissue were below the median had a longer overall survival (median 417 vs 294 days, p = 0.042).
Patients with LAL activity below median had a significant elevation of serum liver enzymes and a worse lipid profile (higher total and LDL cholesterol).
Patients expressing a high level of nuclear pI κB αser32/36 (above median) had a significantly shorter time to death from disease recurrence (P=0.028, Figure 4A).
